Loading
Synovial Cell Cancer / Melanoma / Colorectal Cancer · Observational Study
ClinicalTrials.gov · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a clinical trial registry record for an ongoing observational study evaluating patient eligibility and screening for National Cancer Institute Surgery Branch experimental immunotherapy protocols. No results are posted in this registry entry; the record documents planned enrollment, study conditions, and primary outcome measures (eligibility determination, HLA and mutation screening, test results over 25 years) but does not report efficacy or safety findings.
Observational. Synovial Cell Cancer, Melanoma, Colorectal Cancer, Lung Cancer, Bladder Cancer; age from 18 Years. Intervention: A/Surgery Branch Protocol Candidates. n = 7,000. 1 site: United States.
Estimated enrollment of 7000 participants for screening and evaluation Primary outcome measures include frequency of HLA type, gene-specific mutations, or neoantigen expression in malignant tumors over 25 years Study population includes patients with synovial cell cancer, melanoma, colorectal cancer, lung cancer, and bladder cancer
Registry describes screening and eligibility, not efficacy or safety of experimental therapies.
This registry record describes a screening and evaluation pathway for access to experimental immunotherapy but does not report therapeutic outcomes. Clinicians and patients seeking information on efficacy or safety of NCI-SB protocols must await published results from downstream treatment studies, not this eligibility screening registry.
This is an ongoing observational screening registry with no posted results; it describes planned enrollment and evaluation procedures for experimental immunotherapy protocols, not outcome data.
As stated by the source record.
Quoted from the source exactly as published.
This registry record describes a screening and evaluation pathway for access to experimental immunotherapy but does not report therapeutic outcomes. Clinicians and patients seeking information on efficacy or safety of NCI-SB protocols must await published results from downstream treatment studies, not this eligibility screening registry.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Registry record from ClinicalTrials.gov (NCT00001823). This is a study registration, not published results. Lead sponsor: National Cancer Institute (NCI). Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 7000 participants (ESTIMATED). Conditions: Synovial Cell Cancer, Melanoma, Colorectal Cancer, Lung Cancer, Bladder Cancer. Primary outcome measures: Number of individuals suitable for NCI Surgery Branch clinical research protocols , 25 Years; Frequency of HLA type, gene specific mutations, or expression of neoantigens in malignant tumors , 25 years; Results of screening tests , 25 years. Brief summary: Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols. Eligibility: Patients 18 years or older must meet the minimum eligibility criteria for an NCI-SB treatment protocol. Design Patients will undergo testing and evaluations as required by the appropriate NCI-SB treatment protocol. ...
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.